Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests

Introduction: Imatinib, a tyrosine kinase inhibitor which resulted in much improvement in the treatment of chronic myelogenous leukemia (CML), may adversely affect thyroid gland function. To date, assessment of thyroid function during imatinib therapy has limited to retrospective studies. The aim o...

Full description

Bibliographic Details
Main Authors: Mohammad Ali Mashhadi, Mahmoud Ali Kaykhaei, Mahdi Mohammadi, Mahdi Hashemi, Tahere Mohamadi Fatide
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2014-09-01
Series:International Journal of Hematology-Oncology and Stem Cell Research
Subjects:
Online Access:https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/417